A lower price for rifapentine is just a start — communities need more than discounts to access TB preventive therapy!

Newer medicines for drug-resistant TB are desperately needed, but barriers to access, including high prices, keep them out of reach for most people around the world. 

Civil society activists storm the stage at The Union Conference to demand affordability, transparency and accountability from the TB Alliance.

Pretomanid is just one part of a regimen of multiple drugs that people need. MSF has been calling for the price of a complete DR-TB treatment course to be no higher than $500 per person.

Stop TB Partnership launches online consultation on the draft Global Plan to End TB 2018-2022; Deadline for submissions: 6 November 2019

Médecins Sans Frontières releases the 6th edition of DR-TB Drugs Under the Microscope: 5 Urgent Actions to Improve DR-TB Treatment.

7 million people receive record levels of lifesaving TB treatment but 3 million still miss out. TB remains the top infectious killer in the world.

Médecins Sans Frontières launches a global campaign calling on Johnson & Johnson to lower the price of bedaquiline to no more than US$1 per day.

Médecins Sans Frontières acknowledges the lower price offered to the government of South Africa for delamanid, but calls for it to be significantly lower and expanded to all countries in need.

Donors at the Global Fund's Sixth Replenishment Conference pledged US$14.02 billion for the next three years – the largest amount ever raised for a multilateral health organization, and the largest amount by the Global Fund.